BioCentury | Jan 16, 2020
Company News
Jan. 15 Company Quick Takes: Japan Tobacco gets rights to Dermavant therapy; plus Clovis, BMS, Recordati, BeiGene, Insilico-Pfizer, Novartis
...to treat endogenous Cushing syndrome in adults. Recordati acquired worldwide rights to the inhibitor of CYP11B1...
...cancer 2 early onset; CTLA-4 (CTLA4; CD152) - Cytotoxic T-lymphocyte associated protein 4; CYP11B1 - Cytochrome P450 family 11 subfamily B polypeptide 1...
...1 early onset (BRCA1) Breast cancer 2 early onset (BRCA2) Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) (CTLA4) (CD152) Cytochrome P450 family 11 subfamily B polypeptide 1 (CYP11B1) Epidermal...
...cancer 2 early onset; CTLA-4 (CTLA4; CD152) - Cytotoxic T-lymphocyte associated protein 4; CYP11B1 - Cytochrome P450 family 11 subfamily B polypeptide 1...
...1 early onset (BRCA1) Breast cancer 2 early onset (BRCA2) Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) (CTLA4) (CD152) Cytochrome P450 family 11 subfamily B polypeptide 1 (CYP11B1) Epidermal...